The document discusses guidelines for pharmacovigilance in clinical trials and post-marketing. It outlines responsibilities for monitoring safety, reporting adverse events, and taking action if new risks emerge. Marketing authorization holders must establish systems for safety reporting, literature review, and responding to regulators. Competent authorities conduct inspections and oversight to ensure compliance.